Prestige And Intas Strike International Bevacizumab Deal
US And EU Filings Planned Next Year For HD204 Proposed Avastin Biosimilar
Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.
